Sustained reduction in confirmed disability progression in patients with primary progressive multiple sclerosis treated with ocrelizumab in the open-label extension period of the Phase III ORATORIO trial

被引：0
|
作者：
Wolisnky, J. S. [1 ]
Brochet, B. [2 ]
Montalban, X. [3 ,4 ]
Naismith, R. T. [5 ]
Manfrini, M. [6 ]
Garas, M. [6 ]
Villoslada, P. [7 ]
Model, F. [6 ]
Hubeaux, S. [6 ]
Kappos, L. [8 ]
Hauser, S. L. [9 ]
机构：
[1] UTHealth, McGovern Med Sch, Houston, TX USA
[2] Univ Bordeaux, Bordeaux, France
[3] Univ Toronto, Div Neurol, Toronto, ON, Canada
[4] Vall dHebron Univ Hosp, Barcelona, Spain
[5] Washington Univ, Sch Med, St Louis, MO USA
[6] F Hoffmann La Roche Ltd, Basel, Switzerland
[7] Genentech Inc, San Francisco, CA 94080 USA
[8] Univ Basel, Univ Hosp Basel, Basel, Switzerland
[9] Univ Calif San Francisco, San Francisco, CA 94143 USA
来源：
MULTIPLE SCLEROSIS JOURNAL | 2018年 / 24卷
基金：
新加坡国家研究基金会;
关键词：
D O I：
暂无
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
P910
引用
收藏
页码：490 / 491
页数：2
相关论文
共 50 条
  • [31] Evaluation of no evidence of progression or active disease (NEPAD) in patients with primary progressive multiple sclerosis in the ORATORIO trial
    Wolinsky, Jerry S.
    Montalban, Xavier
    Hauser, Stephen L.
    Giovannoni, Gavin
    Vermersch, Patrick
    Bernasconi, Corrado
    Deol-Bhullar, Gurpreet
    Garren, Hideki
    Chin, Peter
    Belachew, Shibeshih
    Kappos, Ludwig
    ANNALS OF NEUROLOGY, 2018, 84 (04) : 527 - 536
  • [32] Interim Analysis of Open-Label Extension Studies of Sustained Release Fampridine in Patients with Multiple Sclerosis
    Goodman, Andrew D.
    Brown, Ted R.
    Edwards, Keith R.
    Schapiro, Randall T.
    Marinucci, Lawrence N.
    Cohen, Ron
    Blight, Andrew R.
    NEUROLOGY, 2010, 74 (09) : A101 - A101
  • [33] Efficacy and safety of ocrelizumab in primary progressive multiple sclerosis - results of the placebo-controlled, double-blind, Phase III ORATORIO study
    Montalban, X.
    Hemmer, B.
    Rammohan, K.
    Giovannoni, G.
    de Seze, J.
    Bar-Or, A.
    Arnold, D. L.
    Sauter, A.
    Kakarieka, A.
    Masterman, D.
    Chin, P.
    Garren, H.
    Wolinsky, J.
    MULTIPLE SCLEROSIS JOURNAL, 2015, 21 : 781 - 782
  • [34] Efficacy and Safety of Ocrelizumab in Primary Progressive Multiple Sclerosis: Results of the Phase III Double-Blind, Placebo-Controlled ORATORIO Study
    Montalban, Xavier
    Hemmer, Bernhard
    Rammohan, Kottil
    Giovannoni, Gavin
    De Seze, Jerome
    Bar-Or, Amit
    Arnold, Douglas
    Sauter, Annette
    Masterman, Donna
    Fontoura, Paulo
    Garren, Hideki
    Chin, Peter
    Wolinsky, Jerry
    NEUROLOGY, 2016, 86
  • [35] Serum immunoglobulin levels and risk of serious infections in the pivotal Phase III trials of ocrelizumab in multiple sclerosis and their open-label extensions
    Derfuss, T.
    Weber, M. S.
    Hughes, R.
    Wang, Q.
    Sauter, A.
    Koendgen, H.
    Hauser, S. L.
    Bar-Or, A.
    Hartung, H. -P.
    MULTIPLE SCLEROSIS JOURNAL, 2019, 25 : 20 - 21
  • [36] Patient-reported outcomes in the phase III double-blind, placebo-controlled ORATORIO study of ocrelizumab in primary progressive multiple sclerosis
    de Seze, J.
    Montalban, X.
    McDougall, F.
    Sauter, A.
    Deol-Bhullar, G.
    Wolinsky, J.
    MULTIPLE SCLEROSIS JOURNAL, 2016, 22 : 677 - 678
  • [37] Results of an open-label extension trial of sativex (THC:CBD) in patients with multiple sclerosis and symptoms of spasticity
    Collin, C.
    Serpell, M.
    Potts, R.
    MULTIPLE SCLEROSIS, 2007, 13 : S129 - S129
  • [38] Patient-reported outcomes in the phase III double-blind, placebo-controlled ORATORIO study of ocrelizumab in primary progressive multiple sclerosis
    de Seze, Jerome
    Montalban, Xavier
    McDougall, Fiona
    Julian, Laura
    Sauter, Annette
    Deol-Bhullar, Gurpreet
    Wolinsky, Jerry
    MULTIPLE SCLEROSIS JOURNAL, 2017, 23 (01) : 84 - 84
  • [39] Long-term follow-up from the ORATORIO trial of ocrelizumab for primary progressive multiple sclerosis: a post-hoc analysis from the ongoing open-label extension of the random-ised, placebo-controlled, phase 3 trial (vol 19, pg 998, 2020)
    Wolinsky, J. S.
    Arnold, D. L.
    Brochet, B.
    LANCET NEUROLOGY, 2021, 20 (01): : E1 - E1
  • [40] Effect of natalizumab on disease progression in secondary progressive multiple sclerosis (ASCEND): a phase 3, randomised, double-blind, placebo-controlled trial with an open-label extension
    Kapoor, Raja
    Ho, Pei-Ran
    Campbell, Nolan
    Chang, Ih
    Deykin, Aaron
    Forrestal, Fiona
    Lucas, Nisha
    Yu, Bei
    Arnold, Douglas L.
    Freedman, Mark
    Goldman, Myia D.
    Hartung, Hans-Peter
    Kubala Havrdova, Eva
    Jeffery, Douglas
    Miller, Aaron
    Sellebjerg, Finn
    Cadavid, Diego
    Mikol, Dan
    Steiner, Deborah
    LANCET NEUROLOGY, 2018, 17 (05): : 405 - 415
12345